Jazz Pharmaceuticals plc has entered into Amendment No. 4 to its existing credit agreement, extending the maturity date and repricing the interest rates for its outstanding U.S. dollar term loans. The amendment, dated September 23, 2026, was executed by Jazz Financing Lux S.à r.l., a wholly owned subsidiary of the company.
The agreement affects the Tranche B-2 Dollar Term Loans, which were originally incurred on July 19, 2024. Under the terms of the amendment, these loans have been converted into a new tranche of U.S. dollar term loans known as Tranche B-3 Dollar Term Loans. Jazz Financing Lux borrowed an additional $273,310,355.18 in principal to repay the portion of the B-2 loans that was not converted. The total principal amount of the loans following the amendment is $1,895,000,000.
The maturity date for the Tranche B-3 Dollar Term Loans has been extended to May 5, 2033. The loans will amortize in quarterly installments equal to 0.25% of the initial principal amount, with the remaining balance due on the maturity date.
Interest on the new loans is calculated based on either Term SOFR or the prime lending rate, plus an applicable margin. The applicable margin for the Tranche B-3 Dollar Term Loans is 1.75% for Term SOFR borrowings and 0.75% for prime rate borrowings. This represents a decrease of 50 basis points compared to the margin on the previously outstanding Tranche B-2 Dollar Term Loans. The loans are subject to a Term SOFR floor of 0.50% and will not be subject to a credit spread adjustment.
